{"id":401231,"date":"2020-12-16T14:30:35","date_gmt":"2020-12-16T19:30:35","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=401231"},"modified":"2020-12-16T14:30:35","modified_gmt":"2020-12-16T19:30:35","slug":"chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\/","title":{"rendered":"Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"both\">DURHAM, N.C., Dec.  16, 2020  (GLOBE NEWSWIRE) &#8212; CoImmune, Inc. today announced that its CAR-CIK technology was featured at the annual American Society of Hematology (ASH) meeting with an interim update on the phase 1\/2 dose escalation clinical trial in B-cell acute lymphoblastic leukemia (B-ALL). The trial is being conducted at Ospedale San Gerardo, Monza, Italy by principal investigator Andrea Biondi, M.D. and at Papa Giovanni XXIII, Bergamo, Italy by principal investigator Alessandro Rambaldi, M.D. The presentation on was on December 7<sup>th<\/sup> during the immunotherapy session and was given by Dr. Chiara Magnani of the Tettamanti Research Center, Monza, Italy.<\/p>\n<p align=\"both\">The clinical update summarized the results for 15 B-ALL subjects (4 children and 11 adults) infused with a single dose of HLA-matched or partially matched CAR-CIK CD19 cells manufactured from allogeneic peripheral blood donor cells. Following lymphodepletion and subsequent infusion, the CAR-CIK CD19 cells expanded reaching up to 70% of CAR+ T cells in the peripheral blood. Persistence of central memory CAR+ T cells was reported to be measurable up to 9 months after infusion. Of the 9 patients receiving the highest dose levels, 7 (78%) achieved complete remission at day 28 post-infusion. Six of the 7 CRs (86%) achieved minimal residual disease status. Dr. Magnani reported a high profile of safety in all treated patients with only grade 1 or 2 cytokine release syndrome at the highest dose level and no incidence of graft-versus-host disease, neurotoxicity, or dose-limiting toxicity.<\/p>\n<p align=\"both\">\u201cWe are very pleased to continue to observe strong efficacy without serious adverse events and we look forward to continuing our collaboration with CoImmune to further advance the clinical development of this promising technology,\u201d stated study leader, Dr. Andrea Biondi.<\/p>\n<p align=\"both\">\u201cAll of us at CoImmune are very excited by the work we are doing with our colleagues in Italy. We are planning additional clinical trials to be conducted in the United States and Italy targeting B-ALL, chronic lymphocytic leukemia, non-Hodgkin\u2019s lymphoma and acute myelogenous leukemia,\u201d said Charles Nicolette, Chief Executive Officer of CoImmune.<\/p>\n<p align=\"both\">\n        <strong>About CoImmune, Inc.<\/strong>\n      <\/p>\n<p align=\"both\">CoImmune is a privately held clinical stage biotechnology company specializing in the development of immuno-oncology therapies based on its two proprietary platform technologies. Its autologous RNA-loaded dendritic cell technology platform for solid tumors specifically targets each patient\u2019s unique tumor antigens; its allogeneic CAR-CIK technology platform is a variation on CAR-T therapy with greatly reduced toxicity while retaining strong efficacy.<\/p>\n<p align=\"both\">For more information visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=siQx-UAEGW4QlUBNDVfiy5aX0V5zkn_dNQqJoaUkNw0YFXhzZSgj6Ax5oj74X9uaqzrG3TdkUsp1maqU18Sb7w==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.coimmune.com<\/a><\/p>\n<p align=\"both\">\n        <strong>Media Contact:<\/strong>\n      <\/p>\n<p align=\"both\">Lori Harrelson<\/p>\n<p align=\"both\">CoImmune, Inc.<\/p>\n<p align=\"both\">919-287-6349<\/p>\n<p align=\"both\">lharrelson@coimmune.com<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzUwOSMzODg0ODM4IzIxOTQzNTU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/9be9dddd-c5ce-4bfd-8703-57e1f3312ba1\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DURHAM, N.C., Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; CoImmune, Inc. today announced that its CAR-CIK technology was featured at the annual American Society of Hematology (ASH) meeting with an interim update on the phase 1\/2 dose escalation clinical trial in B-cell acute lymphoblastic leukemia (B-ALL). The trial is being conducted at Ospedale San Gerardo, Monza, Italy by principal investigator Andrea Biondi, M.D. and at Papa Giovanni XXIII, Bergamo, Italy by principal investigator Alessandro Rambaldi, M.D. The presentation on was on December 7th during the immunotherapy session and was given by Dr. Chiara Magnani of the Tettamanti Research Center, Monza, Italy. The clinical update summarized the results for 15 B-ALL subjects (4 children and 11 adults) infused with a single dose &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-401231","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DURHAM, N.C., Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; CoImmune, Inc. today announced that its CAR-CIK technology was featured at the annual American Society of Hematology (ASH) meeting with an interim update on the phase 1\/2 dose escalation clinical trial in B-cell acute lymphoblastic leukemia (B-ALL). The trial is being conducted at Ospedale San Gerardo, Monza, Italy by principal investigator Andrea Biondi, M.D. and at Papa Giovanni XXIII, Bergamo, Italy by principal investigator Alessandro Rambaldi, M.D. The presentation on was on December 7th during the immunotherapy session and was given by Dr. Chiara Magnani of the Tettamanti Research Center, Monza, Italy. The clinical update summarized the results for 15 B-ALL subjects (4 children and 11 adults) infused with a single dose &hellip; Continue reading &quot;Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-16T19:30:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzUwOSMzODg0ODM4IzIxOTQzNTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH\",\"datePublished\":\"2020-12-16T19:30:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\\\/\"},\"wordCount\":416,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzUwOSMzODg0ODM4IzIxOTQzNTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\\\/\",\"name\":\"Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzUwOSMzODg0ODM4IzIxOTQzNTU=\",\"datePublished\":\"2020-12-16T19:30:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzUwOSMzODg0ODM4IzIxOTQzNTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzUwOSMzODg0ODM4IzIxOTQzNTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\/","og_locale":"en_US","og_type":"article","og_title":"Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH - Market Newsdesk","og_description":"DURHAM, N.C., Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; CoImmune, Inc. today announced that its CAR-CIK technology was featured at the annual American Society of Hematology (ASH) meeting with an interim update on the phase 1\/2 dose escalation clinical trial in B-cell acute lymphoblastic leukemia (B-ALL). The trial is being conducted at Ospedale San Gerardo, Monza, Italy by principal investigator Andrea Biondi, M.D. and at Papa Giovanni XXIII, Bergamo, Italy by principal investigator Alessandro Rambaldi, M.D. The presentation on was on December 7th during the immunotherapy session and was given by Dr. Chiara Magnani of the Tettamanti Research Center, Monza, Italy. The clinical update summarized the results for 15 B-ALL subjects (4 children and 11 adults) infused with a single dose &hellip; Continue reading \"Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-16T19:30:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzUwOSMzODg0ODM4IzIxOTQzNTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH","datePublished":"2020-12-16T19:30:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\/"},"wordCount":416,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzUwOSMzODg0ODM4IzIxOTQzNTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\/","name":"Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzUwOSMzODg0ODM4IzIxOTQzNTU=","datePublished":"2020-12-16T19:30:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzUwOSMzODg0ODM4IzIxOTQzNTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzUwOSMzODg0ODM4IzIxOTQzNTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chimeric-antigen-receptor-car-modified-cytokine-induced-killer-cell-car-cik-technology-featured-at-ash\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=401231"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401231\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=401231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=401231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=401231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}